ClinicalTrials.gg
Not yet recruitingNCT06974487Updated May 16, 2025

A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects

A Phase 1 interventional study of GZR102 injection and GZR4 injection in Type 2 Diabetes, sponsored by Gan & Lee Pharmaceuticals.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Gan & Lee Pharmaceuticals. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals — 6 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Gan & Lee Pharmaceuticals.

Planned enrollment
15th of 17
30 · median 92
Started
2025
with 4 others
Phase 1
6 of 17
3 open now
Registered
13th of 17
by date

Among the 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals, this one is the 15th largest by planned enrollment, is one of 5 that started in 2025, is one of 6 in phase 1, and was the 13th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals, or all of them as a file.
02

Study summary

This trial is a randomized, double-blind, three-period crossover Phase I Clinical Study conducted in Chinese adult overweight subjects to evaluate the safety, tolerability, PK and PD profiles of a single dose of GZR102 injection versus GZR4 injection and GZR18 injection given separately.

Subjects undergo a screening phase of up to 3 weeks (D-21 to D-3). Eligible subjects are randomized in a 1:1:1:1:1:1 ratio into six dosing sequences, receiving single doses of GZR102 injection, GZR4 injection, and GZR18 injection across 3 cycles. A washout period of at least 1 week separates each cycle.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Subjects sign the Form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and be able to follow the and restrictions specified in this protocol.

      1. Subjects (male or female) age 18-60 years old (inclusive) at the time of signing ICF.
      1. Body weight ≥ 60 kg, (BMI) ≥ 24 kg/m2 and \< 28 kg/m2 at screening.
      1. No birth plan from the signing of ICF to 8 weeks after the last dose, willingness to use effective methods of , and no plan for sperm donation. Females of must not be lactating and must have negative results of blood pregnancy tests at screening and predose.

Exclusion criteria

Exclusion Criteria:

    1. History of drug abuse prior to screening; or positive results for drug abuse at screening.

      1. History of alcohol abuse defined as an average alcohol intake of more than 14 units per week (1 standard unit = 360 mL of beer or 150 mL of 12% wine or 45 mL of 40% spirits) within 6 months prior to screening.
      1. Subjects who smoked > 5 cigarettes/day within 3 months prior to screening or who cannot stop using any tobacco products during the study.
      1. Subjects with a history of allergy to ≥ 2 drugs, or known or intolerance to the IMP or similar products and their .
      1. Presence of any suspected and/or definitively diagnosed at screening; or patients diagnosed with other malignancies within 5 years; 6. Previous or current medical history of cardiovascular, hematological, respiratory, digestive, urinary, endocrine/metabolic, neurological, or psychiatric disorders that, in the investigator's judgment, may affect the study outcomes.
      1. History of acute or chronic pancreatitis, biliary/gallbladder diseases , or pancreatic injury.
      1. Major surgery (including but not limited to procedures requiring general anesthesia) within 3 months prior to screening; or history of organ transplantation (except corneal transplantation performed more than 4 months prior to screening); or incomplete recovery from illness, trauma, or surgery at screening (e.g., significant impairment in daily living or working capacity compared to pre-illness/injury/surgery status); or planned surgery during the study period.
      1. Blood donation or significant blood loss (> 400 mL), or blood transfusion in the 3 months prior to screening.
      1. Presence of any abnormalities in 12-lead , vital signs (blood pressure, respiration, pulse rate, body temperature), physical examination, imaging examination, or laboratory tests (hematology, urinalysis, blood chemistry, coagulation function, serum amylase, serum lipase, calcitonin) as determined by the investigator at screening..
      1. Positive screening results for surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody, or treponema pallidum antibody infection at screening.
      1. History of organ transplantation, or acquired or congenital immune system disorders.
      1. Participation in a clinical study of another medicinal product (IMP), surgery, or device within 3 months before screening, or within 5 half-lives of the previous IMP (whichever is longer). Or plan to participate in another clinical study of an IMP, surgery, or device before completing all scheduled assessments in the clinical study.
      1. Subjects who have used GLP-1 receptor agonists or drugs with the mechanism of action of GLP-1R agonists.
      1. Subjects who are allergic to any food or have specific dietary requirements and cannot adhere to a standardized diet.
      1. History of needle or blood phobia, or difficulty with blood collection; or inability/unwillingness to undergo repeated venipuncture.
      1. Subjects who were considered not suitable for the clinical study due to other reasons at the discretion of the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    GZR102 injection

    Participants will get a single dose of GZR102 injection (fixed-ratio combination of GZR4 and GZR18).

    Drug: GZR102 injection

  • Active comparator
    GZR4 injection

    Participants will get a single dose of GZR4 injection

    Drug: GZR18 injection

  • Active comparator
    GZR18 injection

    Participants will get a single dose of GZR18 injection

    Drug: GZR4 injection

Interventions

  • DrugGZR102 injection

    Participants will get a single dose of GZR102 injection (fixed-ratio combination of GZR4 and GZR18).

  • DrugGZR4 injection

    Participants will get a single dose of GZR4 injection

  • DrugBofanglutideStudies of BofanglutideBofanglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will get a single dose of GZR18 injection

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose.

    Time frame: Day 36 (end of period)

Secondary outcomes

  1. AUC0-inf

    Area under the plasma concentration-time curve at 0 h to infinity after a single dose.

    Time frame: Day 36 (end of period)

  2. TEAEs

    Treatment-emergent adverse events in terms of number of subject

    Time frame: Day 36 (end of period)

  3. Hypoglycemia

    Number of subjects, number of events and incidence of treatment-emergent hypoglycemia.

    Time frame: Day 36 (end of period)

  4. Immunogenicity

    Including anti-drug antibody (ADA) and neutralizing antibody (NAb).

    Time frame: Day 36 (end of period)

  5. Cmax

    Maximum plasma concentration

    Time frame: Day 36 (end of period)

07

Study locations

1 site
  • Study site 01
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Sep 2025, 4 months later.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 4 months is below that.

Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 16, 2025
StartEst.
May 8, 2025
Primary completionEst.
Sep 30, 2025
CompletionEst.
Sep 30, 2025
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06974487
Responsible party
Sponsor
First posted
May 16, 2025
Start date
May 8, 2025 (estimated)
Primary completion
Sep 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
May 16, 2025

Study contacts

xuepeng Chen
Contact
xuepeng.chen@ganlee.com
010-56456739

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion